Join to access to all OVN content. Join for Free
Metrics: Quality vs. Quantify and how the game has changed
MSL metrics Medical Science Liaison COVID impact on MSLs MSL managers emotional intelligence

Metrics: Quality vs. Quantify and how the game has changed


Share This Article


Summary

In this episode, Charlie Cook from Takeda joins Tom Caravela to explore the evolving landscape of MSL metrics before, during, and after COVID. They discuss the origins and strategic alignment of these metrics throughout drug lifecycles and the complexities of tracking them across different territories. The conversation delves into the impact of metrics on MSL behavior, emphasizing flexibility in interactions with Key Opinion Leaders (KOLs) and the challenges of a hybrid work environment. Charlie highlights the crucial role of MSL managers in communicating value and evaluating performance. The episode concludes with insights into essential skills for future MSLs, such as emotional intelligence and effective virtual communication.

Charlie Cook, Director MSLs at Takeda, discusses metrics and how the game has changed since Covid 19

Charlie shares….

πŸ‘‰ His views on Quality vs Quantity

πŸ‘‰ The importance of focusing on strategic goals

πŸ‘‰ Advice for the future of Medical Affairs

πŸ‘‰ Why MSLs need to communicate VALUE

Click for Source
MSL metrics, Medical Science Liaison, COVID impact on MSLs, MSL managers, emotional intelligence

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN